Researchers have designed and tested a peptide derived from a human cell-surface receptor that blocks herpes simplex virus type 1 (HSV-1) infection in laboratory tests, reporting a modified version that protects roughly sixty percent of treated cells without detectable toxicity. The study, published as an original article in the journal Amino Acids, addresses a persistent global health problem: HSV infections recur frequently and current drug strategies face challenges from resistance.
The team targeted a critical early step in infection, the interaction between the viral glycoprotein gD and HVEM, a receptor on host cells. Their starting point was a native peptide sequence, designated NP (KEACGELTGTVCEP), derived from HVEM itself. In vitro testing showed that this unmodified peptide was not cytotoxic and provided approximately fifty percent antiviral protection.
These analyses guided the creation of seven modified variations of the original peptide. One variant, named F4, showed improved binding affinity in docking studies. Its sequence, RQACGELTGTVCEP, differs from the native peptide at the amino-terminus, a change the computational work linked to stronger interaction with the viral target.
In vitro experiments confirmed that F4 acts in a dose-dependent manner, achieving 60.58 percent protection at a concentration of 250 micrograms per millilitre, again without toxicity. The authors note that F4 was relatively less effective than the existing antiviral drug Acyclovir in their comparison. Even so, they describe the modified peptide as having promising therapeutic potential, given its demonstrated antiviral efficacy and favourable safety profile in cell culture.
The authors argue that this integrated approach offers a strong foundation for future anti-HSV drug development, particularly as resistance and recurrence continue to limit current therapeutic options. As the findings come from in vitro testing of a peptide still in the early design stage, further development would be needed before any clinical application could be considered.
Subject of Research: Design of host-derived antiviral peptides targeting HSV-1 entry
Article Title: Design, development and enhanced efficacy of host-derived antiviral peptides to prevent herpes simplex virus type 1 infection
Article References: Shrenik Patil, S., Garge, R. N., Aithal, A. P., Srinivasan, K., Rahangdale, R., & Hariharapura, R. C. (2026). Design, development and enhanced efficacy of host-derived antiviral peptides to prevent herpes simplex virus type 1 infection. Amino Acids. https://doi.org/10.1007/s00726-026-03552-y
Image Credits: AI Generated
DOI: 10.1007/s00726-026-03552-y
Keywords: herpes simplex virus 1, antiviral peptides, HVEM, glycoprotein gD, molecular docking, molecular dynamics, drug resistance, in vitro, peptide design, Amino Acids, Design, development
News Source: Kristina Jarvis. (October 30, 2026). Host-derived peptide shows antiviral activity against herpes simplex virus type 1 in vitro. Scienmag.
